CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more
CSPC Pharmaceutical Group Limited (CSPCY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.013x
Based on the latest financial reports, CSPC Pharmaceutical Group Limited (CSPCY) has a cash flow conversion efficiency ratio of 0.013x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($455.84 Million) by net assets ($34.86 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CSPC Pharmaceutical Group Limited - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how CSPC Pharmaceutical Group Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CSPC Pharmaceutical Group Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CSPC Pharmaceutical Group Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tower Semiconductor Ltd
NASDAQ:TSEM
|
0.014x |
|
CK Asset Holdings Limited
PINK:CNGKY
|
0.011x |
|
ASICS Corporation
PINK:ASCCF
|
0.147x |
|
Standard Bank Group Ltd PK
PINK:SGBLY
|
0.252x |
|
China Northern Rare Earth Group High-Tech Co Ltd
SHG:600111
|
0.060x |
|
Sieyuan Electric Co Ltd
SHE:002028
|
0.079x |
|
NN Group N.V
PINK:NNGPF
|
0.001x |
|
Bureau Veritas SA
PINK:BVVBY
|
0.177x |
Annual Cash Flow Conversion Efficiency for CSPC Pharmaceutical Group Limited (2003–2024)
The table below shows the annual cash flow conversion efficiency of CSPC Pharmaceutical Group Limited from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $33.87 Billion | $4.53 Billion | 0.134x | +8.59% |
| 2023-12-31 | $33.89 Billion | $4.18 Billion | 0.123x | -51.00% |
| 2022-12-31 | $30.31 Billion | $7.63 Billion | 0.252x | +77.97% |
| 2021-12-31 | $32.79 Billion | $4.64 Billion | 0.141x | -42.56% |
| 2020-12-31 | $27.38 Billion | $6.74 Billion | 0.246x | +43.18% |
| 2019-12-31 | $22.01 Billion | $3.78 Billion | 0.172x | -31.34% |
| 2018-12-31 | $15.53 Billion | $3.89 Billion | 0.250x | +17.35% |
| 2017-12-31 | $12.87 Billion | $2.75 Billion | 0.213x | -27.90% |
| 2016-12-31 | $8.82 Billion | $2.61 Billion | 0.296x | +5.76% |
| 2015-12-31 | $6.73 Billion | $1.88 Billion | 0.280x | -11.62% |
| 2014-12-31 | $5.70 Billion | $1.81 Billion | 0.317x | +139.57% |
| 2013-12-31 | $4.82 Billion | $636.74 Million | 0.132x | +74.80% |
| 2012-12-31 | $5.30 Billion | $401.05 Million | 0.076x | -79.72% |
| 2011-12-31 | $777.73 Million | $289.99 Million | 0.373x | -75.25% |
| 2010-12-31 | $569.69 Million | $858.23 Million | 1.506x | +412.14% |
| 2009-12-31 | $4.69 Billion | $1.38 Billion | 0.294x | -11.09% |
| 2008-12-31 | $4.04 Billion | $1.34 Billion | 0.331x | +112.95% |
| 2007-12-31 | $5.42 Billion | $842.64 Million | 0.155x | +77.81% |
| 2006-12-31 | $2.65 Billion | $231.44 Million | 0.087x | +16.16% |
| 2005-12-31 | $2.59 Billion | $194.56 Million | 0.075x | -65.99% |
| 2004-12-31 | $2.42 Billion | $534.65 Million | 0.221x | -55.39% |
| 2003-12-31 | $2.26 Billion | $1.12 Billion | 0.496x | -- |